首页> 外文期刊>Drug Design, Development and Therapy >Combination therapy of ursodeoxycholic acid and budesonide for PBC–AIH overlap syndrome: a meta-analysis
【24h】

Combination therapy of ursodeoxycholic acid and budesonide for PBC–AIH overlap syndrome: a meta-analysis

机译:熊去氧胆酸和布地奈德联合治疗PBC-AIH重叠综合征的荟萃分析

获取原文
       

摘要

Abstract: In this study, a meta-analysis of randomized controlled trials comparing ursodeoxycholic acid (UDCA) monotherapy with combination therapies utilizing UDCA and budesonide was performed. We found that combination therapy with UDCA and budesonide was more effective than UDCA monotherapy for primary biliary cirrhosis–autoimmune hepatitis overlap syndrome. Moreover, compared to prednisone, budesonide has fewer side effects.
机译:摘要:在这项研究中,进行了一项荟萃分析,比较了熊去氧胆酸(UDCA)单一疗法与联合使用UDCA和布地奈德的联合疗法的随机对照试验。我们发现在原发性胆汁性肝硬化-自身免疫性肝炎重叠综合征中,UDCA和布地奈德联合治疗比UDCA单药治疗更有效。而且,与泼尼松相比,布地奈德具有更少的副作用。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号